Merigolix (INNTooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids.[1][2][3][4][5] It is taken by mouth.[1] The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical.[1][2] As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.[1][2]

See also

References

  1. ^ a b c d e "Merigolix". AdisInsight. 28 October 2024. Retrieved 24 February 2025.
  2. ^ a b c "Delving into the Latest Updates on Merigolix with Synapse". Synapse. 22 February 2025. Retrieved 24 February 2025.
  3. ^ Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J (December 2017). "Recent Development of Non-Peptide GnRH Antagonists". Molecules. 22 (12): 2188. doi:10.3390/molecules22122188. PMC 6149776. PMID 29232843.
  4. ^ Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (2019). "Uterine fibroids: an update on current and emerging medical treatment options". Therapeutics and Clinical Risk Management. 15: 157–178. doi:10.2147/TCRM.S147318. PMC 6350833. PMID 30774352.
  5. ^ Angioni S, D'Alterio MN, Daniilidis A (2021). "Highlights on Medical Treatment of Uterine Fibroids". Current Pharmaceutical Design. 27 (36): 3821–3832. doi:10.2174/1381612826666210101152820. PMID 33388011.
Allikas: https://en.wikipedia.org/wiki/Merigolix
No tags for this post.